The current prospective, randomized, double-blind study was conducted from June 2016 to March 2018. The study protocol was approved by the Ethics Committee of Tanta University hospitals, Tanta, Egypt (30663/12/15) and registered at the Pan African Clinical Trials Registry (PACTR201701001959580). After obtaining written informed consent, 80 patients of either gender, aged 18 - 60 years, ASA I-III, and difficult airway intubation due to laryngeal mass who were candidates for laryngeal mass biopsy under general anesthesia were enrolled in the study. Patients with bleeding disorders, nasal mass, allergy to any of the drugs under study, uncontrolled systemic diseases with excessive use of analgesics or long term sedative medication and the ones that were uncooperative or refused to give informed consent were excluded from the study.
Patients were randomly assigned 1:1 to administer one of the two different sedative infusions for AFOI, dexmedetomidine-propofol (group D; n = 40) or ketofol (group K; n = 40). The randomization was done using a computer-generated random numbers concealed in sealed envelopes showing the group assignment. A nurse, who was blind to the study and data gathering, made group assignments by reading the number in the envelope. A senior anesthesiologist, who was blind to the group identities, performed AFOI in all subjects. An anesthesiologist, who was blind to the randomization, prepared the drugs. Also, the observer was entirely blind to the groups or medication administered to the patients.
A preoperative visit one day prior surgery was performed. History taking, systemic examination (extensive airway examination and the difficulty of intubation assessed both by the clinical examination and indirect laryngoscope), and preoperative investigations were performed. All patients were ordered to fast for at least six hours before the procedure. Patients were informed about the technique of AFOI with sedation, as well as their required collaboration.
Patients received standardized premedication in the form of diazepam tablet 10 mg and ranitidine tablet 150 mg given with sips of water two hours before surgery and intramuscular atropine
0.01 mg/kg was administered 30 minutes before application of topical anesthesia.
Once in the operating theatre, standard monitoring was performed with the aid of pulse oximetry, electrocardiography, and noninvasive arterial blood pressure, and 100% oxygen (2 L/minute) was delivered via nasal cannula.
Preparation of the nasal mucosa was achieved by instillation of 0.1% xylometazoline hydrochloride nasal drops and nasal packing was performed using cotton-tipped swabs soaked in 2% lidocaine and epinephrine (1:200000) solution. The more patent nostril during nasal packing was selected for nasal intubation. A 10% lidocaine was sprayed onto the oral cavity to decrease the gag reflex.
The medications were infused via 50-mL syringe pumps (Injectomat Agilia IS, Fresenius, 018090/22716658Brezins, France) labeled as I, II, III, and IV. Syringe I contained dexmedetomidine (2 mL DEX (200 μg) added to 48 mL of 0.9% saline solution; concentration of 4 μg/mL) to be infused at a rate of 1 μg/kg for the first 10 minutes as intravenous bolus dose followed by infusion of 0.5 μg/kg/hour; syringe II contained ketofol in a ratio of 2:1 ( 20 mL of 1% propofol added to 2 mL ketamine (50 mg/mL) plus 28 mL of 0.9% saline; concentration of 4 mg/mL propofol and 2 mg/mL ketamine) and an initial loading dose of 0.125 mL/kg over 10 minutes was given followed by the infusion of 0.125 mL/kg/hour; syringe III contained 0.9% normal saline, while syringe IV contained propofol (20 mL of 1% propofol added to 30 ml of 0.9% saline; concentration of 4 mg/mL) to be infused at the same rate of dexmedetomidine and ketofol, respectively. Patients in the D group received I and IV infusions, while patients in the K group received II and III infusions.
Patient’s sedation level was evaluated using Ramsay sedation scale (RSS) throughout the whole procedure (1: anxious, agitated or restless; 2: cooperative, oriented, and tranquil; 3: sedated, but responds to command; 4: asleep with brisk response to stimulus; 5: asleep with sluggish response to stimulus; and 6: asleep with no response). If RSS was < 3 at any time during the procedure and if the patient or the anesthetist were uncomfortable, rescue propofol doses (20 mg increments) were given.
3.1. Fiberoptic Intubation Technique
When sufficient level of sedation (RSS ≥ 3) was obtained, tracheal intubation was conducted using fiber-optic endoscope (Karl Storz, 1130 1BN1, Germany). Epidural catheter inserted in the suction channel of fiber-optic endoscope was used to produce modified topical anesthesia of the airway as described by Liu et al. (
3), by the spray-as-you-go technique onto the glottis and below vocal cords using 2% lidocaine. Once entering the trachea, the endotracheal tube was slided on the bronchoscope, and intubation was confirmed using capnography. The endotracheal tube was fixed, infusion of the study drugs was discontinued and general anesthesia was induced to all groups using propofol 1 mg/kg, fentanyl 1 µg/kg, and atracurium 0.5 mg/kg. The maintenance of anesthesia was performed using a balanced anesthetic technique of isoflurane in oxygen, and incremental doses of atracurium (0.1 mg/kg). At the end of the operation, extubation was performed after neuromuscular block reversing with neostigmine (0.05 mg/kg) and atropine (0.01 mg/kg). The patients were then transferred to recovery room and closely monitored for 24 hours.
3.2. Outcome Variables
The primary outcome variable was time to reach sufficient sedation level defined as the interval between the drug infusions and RSS ≥ 3. Secondary outcomes were as follows:
-Intubation time (time from insertion of the fiberoptic bronchoscope throughout the nose till confirmation of intubation with capnography) and number of intubation trials
-Number of patients in need of rescue propofol in each group
-Patient’s discomfort score (0: no discomfort; 1: probable mild discomfort, no patient resistance; 2: restless patient, minimal patient resistance; 3: restless patient, severe patient resistance)
-Patient’s tolerance to endoscopy and intubation on a five-point scale (1: no reaction, 2: slight grimacing, 3: heavy grimacing, 4: verbal objection, and 5: defensive movement of head and hands)
-Cough score (1: no cough, 2: slight cough (no more than two coughs per sequence), 3: moderate cough (3 - 5 coughs per sequence), 4: severe cough ( > 5 coughs per sequence)
-Heart rate (HR) and mean arterial blood pressure (MAP) were recorded at the following points: on arrival to the operating room as a baseline (T0), after bolus sedation immediately prior to fiberoptic intubation (T1), at the passage of the fiber-optic endoscope through vocal cords (T2), at the time of intubation (T3), then at 1, 3, and 5 minutes after intubation (T4, T5, T6, respectively). Hypotension, defined as reduction in MAP < 20% of baseline measurement, was managed by intravenous fluid and bolus dose of 5 mg ephedrine, repeated if necessary. Bradycardia, defined as HR < 60 beat/minute, was treated with 0.01 mg/kg atropine.
-Airway obstruction was evaluated by airway obstruction score (1: patent airway; 2: airway obstruction relieved by neck extension; 3: airway obstruction requiring jaw thrust)
-Hypoxic episodes (SpO2 < 92%) or apnea (cessation of spontaneous breathing for more than 20 seconds) were recorded and managed by airway support and assisted ventilation using bag and mask technique.
-Patient’s satisfaction 24 hours post-operation (very satisfied, satisfied, dissatisfied, very dissatisfied)
-Anesthesiologist’s satisfaction score (1: excellent, 2: good, 3: fair, 4: poor) was also recorded.
Failure of AFOI, due to developing severe resistance during the procedure, was considered as the study failure, and induction was performed with standard doses of propofol, fentanyl, and rocuronium; then, intubation was performed with the fiberoptic bronchoscope and the availability of a cricothyrotomy set as well as the ear, nose, and throat team ready to perform emergency tracheostomy if needed.
3.3. Statistical Analysis
Sample size calculation suggested a minimum of 37 patients in each group based on the results of a previous study (
12) to detect a significant reduction in time to reach RSS ≥ 3 of at least 2.2 minutes at α error of 0.05, standard deviation of 2.6, and the study power of 95%. Therefore, 40 cases were enrolled in each group to overcome possible dropouts. SPSS version 16 (SPSS Inc., Chicago, IL, USA) was utilized for statistical analysis. Normality of data was assessed using the Shapiro-Wilk test. Numerical variables were compared between the two groups utilizing the Student independent
t test for data with normal distribution or by the Mann -Whitney U test, if otherwise. Categorical variables were presented as patients’ number and percentage and analyzed by the Chi-square or the Fisher exact test where appropriate. P value < 0.05 was considered significant.